CO6460767A2 - Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas - Google Patents

Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas

Info

Publication number
CO6460767A2
CO6460767A2 CO11155150A CO11155150A CO6460767A2 CO 6460767 A2 CO6460767 A2 CO 6460767A2 CO 11155150 A CO11155150 A CO 11155150A CO 11155150 A CO11155150 A CO 11155150A CO 6460767 A2 CO6460767 A2 CO 6460767A2
Authority
CO
Colombia
Prior art keywords
dexmedetomidine
methods
compositions
sublingual compositions
pharmaceutically acceptable
Prior art date
Application number
CO11155150A
Other languages
English (en)
Inventor
Geraldie Anne Henwood
Randall Jerome Mack
Christopher Thomas Sharr
John Joseph Koleng Jr
Original Assignee
Recro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43085620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6460767(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recro Pharma Inc filed Critical Recro Pharma Inc
Publication of CO6460767A2 publication Critical patent/CO6460767A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0625—Mouth

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se provee una composición farmacéutica analgésica, transmucosal oral que comprende dexmedetomidina, o una sa farmacéuticamente aceptable de ella y un excipiente farmacéuticamente aceptable, y el uso de dichas composiciones en el tratamiento o prevención del dolor sin sedación importante.
CO11155150A 2009-05-15 2011-11-15 Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas CO6460767A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17873009P 2009-05-15 2009-05-15

Publications (1)

Publication Number Publication Date
CO6460767A2 true CO6460767A2 (es) 2012-06-15

Family

ID=43085620

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11155150A CO6460767A2 (es) 2009-05-15 2011-11-15 Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas

Country Status (21)

Country Link
US (1) US20110021588A1 (es)
EP (2) EP3305281A1 (es)
JP (2) JP6172938B2 (es)
KR (1) KR101859486B1 (es)
CN (2) CN106511273A (es)
AU (1) AU2010248776B2 (es)
BR (1) BRPI1010567A2 (es)
CA (1) CA2762107A1 (es)
CL (1) CL2011002858A1 (es)
CO (1) CO6460767A2 (es)
CR (1) CR20110596A (es)
DO (1) DOP2011000354A (es)
EC (1) ECSP11011459A (es)
HN (1) HN2011003011A (es)
IL (1) IL216159A (es)
MX (1) MX2011011950A (es)
NZ (1) NZ596976A (es)
PE (1) PE20120713A1 (es)
RU (1) RU2572692C2 (es)
SG (1) SG175979A1 (es)
WO (1) WO2010132882A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
EP2787970B1 (en) 2011-12-11 2018-04-11 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
CA2865593A1 (en) * 2012-02-27 2013-09-06 Eye Therapies Llc Compositions and methods for the treatment of migraine
ES2659271T3 (es) 2012-10-15 2018-03-14 Orion Corporation Método veterinario para aliviar la aversión al ruido
EP2792352A1 (en) * 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
US20150273215A1 (en) * 2014-03-26 2015-10-01 Pacesetter, Inc. Systems and methods for assessment of pain and other parameters during trial neurostimulation
EP3054930B1 (en) * 2013-10-07 2020-12-02 Teikoku Pharma USA, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
WO2015054059A2 (en) 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
CN105764494A (zh) 2013-10-07 2016-07-13 帝国制药美国公司 右旋美托咪啶经皮递送装置及其使用方法
RU2557882C1 (ru) * 2014-07-08 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Способ проведения премедикации при плановом хирургическом лечении
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
JP7065871B2 (ja) * 2016-12-13 2022-05-12 オリオン コーポレーション イヌの分離不安症の治療における使用のためのデクスメデトミジンまたはメデトミジン
KR20240031326A (ko) * 2016-12-31 2024-03-07 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
MX2020014000A (es) 2018-06-27 2021-06-15 Bioxcel Therapeutics Inc Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
CN112138250B (zh) * 2019-06-28 2023-04-14 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
MX2022000709A (es) 2019-07-19 2022-05-19 Bioxcel Therapeutics Inc Regimenes de tratamiento con dexmedetomidina no sedante.
CN113827590A (zh) * 2020-06-08 2021-12-24 四川普锐特药业有限公司 右美托咪定在助眠药物制备中的应用
US20220031664A1 (en) * 2020-07-28 2022-02-03 Melt Pharmaceuticals, Inc. Pharmaceutical compositions comprising antiemetics and alpha-2-adrenergic receptor agonists and methods of using the same for anesthesiological applications
WO2024055042A1 (en) * 2022-09-11 2024-03-14 Bioxcel Therapeutics, Inc. Methods for treating agitation in community settings
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN118542852B (zh) * 2024-07-30 2024-10-01 山东则正医药技术有限公司 包含经口给药的右美托咪定舌下膜组合物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
SG47527A1 (en) * 1990-12-05 1998-04-17 Gen Hospital Corp Devices for treating pulmonary vasoconstriction and asthma
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5571840A (en) * 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US5713907A (en) * 1995-07-20 1998-02-03 Endotex Interventional Systems, Inc. Apparatus and method for dilating a lumen and for inserting an intraluminal graft
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US6716867B1 (en) * 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
PT1117390E (pt) * 1998-10-02 2005-01-31 3M Innovative Properties Co Sistemas de distribuicao de farmacos originarios da mucosa e aplicacoes em animais
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
AUPR184500A0 (en) * 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
WO2002094238A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20090117054A1 (en) * 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
RU2432950C2 (ru) * 2006-01-25 2011-11-10 Инсис Терапьютикс Инк. Подъязычный спрей на основе фентанила
DK1986642T3 (da) * 2006-02-13 2014-02-03 Orient Pharma Samoa Co Ltd Kombination af alfa-2-receptoragonist (clonidin) og et antimuscarinmiddel (oxybutynin) til behandling af sialorrhoea
US20080021074A1 (en) * 2006-06-29 2008-01-24 Questcor Pharmaceuticals, Inc. Pharmaceutical Compositions and Related Methods of Treatment
CN101057830A (zh) * 2007-05-10 2007-10-24 北京天川军威医药技术开发有限公司 盐酸纳洛酮舌下喷雾给药系统或组合物及其制备方法

Also Published As

Publication number Publication date
AU2010248776A1 (en) 2012-01-12
WO2010132882A2 (en) 2010-11-18
IL216159A (en) 2015-10-29
JP2012526854A (ja) 2012-11-01
EP2429521B1 (en) 2017-10-18
BRPI1010567A2 (pt) 2016-03-15
CA2762107A1 (en) 2010-11-18
WO2010132882A3 (en) 2011-03-31
KR20120008058A (ko) 2012-01-25
CN102639131A (zh) 2012-08-15
CL2011002858A1 (es) 2012-06-22
NZ596976A (en) 2014-05-30
JP6172938B2 (ja) 2017-08-02
ECSP11011459A (es) 2012-01-31
WO2010132882A8 (en) 2011-12-29
AU2010248776B2 (en) 2013-06-06
RU2572692C2 (ru) 2016-01-20
CN106511273A (zh) 2017-03-22
SG175979A1 (en) 2011-12-29
EP2429521A2 (en) 2012-03-21
HN2011003011A (es) 2014-12-01
EP2429521A4 (en) 2013-08-21
CR20110596A (es) 2012-03-26
DOP2011000354A (es) 2012-07-15
US20110021588A1 (en) 2011-01-27
IL216159A0 (en) 2012-01-31
JP2016029055A (ja) 2016-03-03
PE20120713A1 (es) 2012-07-08
RU2011151059A (ru) 2013-06-20
EP3305281A1 (en) 2018-04-11
KR101859486B1 (ko) 2018-06-28
MX2011011950A (es) 2012-02-21

Similar Documents

Publication Publication Date Title
CO6460767A2 (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
CL2008001855A1 (es) Compuestos ciclicos condensados derivados del boro; composicion farmaceutica; y uso en el tratamiento y/o prevencion de una enfermedad infecciosa.
CL2012000794A1 (es) Composicion farmaceutica solida de desintegracion oral que comprende 20 mg o menos de un un corticoesteroide y un desintegrador; tableta que se desintegra oralmente; y su uso en el tratamiento de una afeccion inflamatoria del tracto gastrointestinal como inflamacion del esofago, glosis, epiglotis, amigdalas, orofaringea, entre otras.
CL2008001157A1 (es) Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio.
PE20142368A1 (es) Formas de dosificacion del tapentadol novedosas y potentes
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
PA8809601A1 (es) Combinación anti-retroviral
NO20084826L (no) Ny administrasjonsform av racecadotril
EA201001643A1 (ru) Пероральное введение периферически действующих опиоидных антагонистов
MX2009007784A (es) Composiciones de tiacumicinas estables.
MY152951A (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
EA201170512A1 (ru) Композиция для перорального введения
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
PE20120956A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide
AR065917A1 (es) Composicion farmaceutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor
CL2008003182A1 (es) Compuestos derivados de 1,2,4-triazol-3-amino; composicion farmaceutica; y su uso en el tratamiento del dolor, reflujo gastroesofagico, ansiedad, sindrome del intestino irritable.
CL2008000227A1 (es) Composicion farmaceutica que comprende una combinacion de uso oral de tramadol y ketoprofeno; y uso en el tratamiento del dolor.
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.
MD2516C2 (ro) Remediu medicamentos antiinflamator, antiseptic şi antifungic sub formă de gel
CR20120617A (es) Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
ECSP099649A (es) Composicion farmaceutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor
ECSP12012331A (es) Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso

Legal Events

Date Code Title Description
FG Application granted